Treatment of in-stent restenosis remains a therapeutic challenge. Twenty-seven lesions with in-stent restenosis were treated with non–polymer-based paclitaxel-eluting stents. At 6-month follow-up, in-stent late loss was 0.44 ± 0.54 mm and the restenosis rate was 20%, indicating effective treatment for reduction of recurrent restenosis.